Dec-2007
How Effective Is Pegylated Interferon plus Ribavirin
for HCV Genotype 1 Patients Over Age 50?
Epidemiology and Treatment Response of Genotype 5 HCV;
Researchers Find New Seventh Genotype
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients
with hepatitis C virus genotype 2 or 3 and rapid virological response
-
Nov 2007
Response-guided therapy in a prospective trial of
peginterferon alfa-2a (40KD)/ribavirin treatment in patients with HCV
genotype 1 or 4 -
Insulin Resistance Predicts HCV Progression in
Genotype 1
HCV patients with genotype 2 or 3 who do not achieve a
rapid virologic response (RVR) with peginterferon alfa-2a (40KD) (PEGASYS)
and ribavirin (COPEGUS) are not easy to treat: an analysis of non-RVR
patients from the ACCELERATE study
:
High rates of sustained virologic response (SVR) in
patients >50 years infected with HCV genotype 1 with positive prognostic
factors treated with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®)
Differentiation of early virologic response (EVR) into
RVR, complete EVR (cEVR) and partial EVR (pEVR) allows for a more precise
prediction of SVR in HCV genotype 1 patients treated with peginterferon
alfa-2a (40KD) (PEGASYS) and ribavirin (COPEGUS)
Outcomes in HIV-HCV co-infected genotype 1 patients
treated with peginterferon alfa-2a (40KD) plus ribavirin 1000 or 1200
mg/day: predictions based on generalized additive models
High chance of cure in HCV genotype 1 patients with a
low viral load achieving an RVR treated for 24 weeks with pegylated
interferon alfa-2a (PEGASYS) plus ribavirin (COPEGUS): prospective,
randomized, controlled study comparing 24 & 48 weeks of treatment
-
Daily consensus interferon versus
peg-interferon alfa2b with weight based or 800 mg ribavirin in
treatment-naive patients with chronic hepatitis C genotypes 2 or 3
Daily consensus interferon versus
peg-interferon alfa2b with weight based ribavirin in treatment-naive
patients with chronic hepatitis C genotype 1
U.S. multicenter pilot study of
daily consensus interferon (infergen) plus ribavirin for
“difficult-to-treat” HCV genotype 1 patients: tolerance and on-therapy
virologic response.
Combination Therapy with HCV Protease Inhibitor
Telaprevir (VX-950) plus Pegylated Interferon and Ribavirin Produces
Sustained Response in 61% of Genotype 1 Patients
Future Studies Should Avoid Combining Genotype 2 and
Genotype 3 Patients Due to Lower Response Rate in the Genotype 3 Population
Ultra Rapid Virological Response at Week 2 Predicts
Sustained Response in HCV Genotype 3 Patients with High Viral Load: The
Get-C Study
Antiviral, pharmacokinetic and safety data
for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1
trial in HCV genotype 1 infected patients
Rapid and early virological response rates are
increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard
ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety
analysis of the induction phase of the CHARIOT study
-
Evaluation of Viral Variants During a Phase 2
Study (PROVE2) of Telaprevir with Peg-interferon alfa-2a and Ribavirin in
Treatment-naïve HCV Genotype 1-Infected Patients
Phase 2a study to evaluate the safety and tolerability
and anti-viral of 4 doses of a novel, controlled-release interferon-alfa 2b
(Locteron) given every 2 weeks for 12 weeks in treatment-naive patients with
chronic hepatitis C (genotype 1)
Antiviral Activity, Pharmacokinetics, Safety,
and Tolerability of R7128, a Novel Nucleoside HCV RNA Polymerase Inhibitor,
Following Multiple, Ascending, Oral Doses in Patients with HCV Genotype 1
Infection Who have Failed Prior Interferon Therapy
A high barrier to resistance may contribute to the
robust antiviral effect demonstrated by R1626 in HCV genotype 1-infected
treatment-naive patients -
Rapid and early virological response rates are
increased with 12 week 360 μg/wk peginterferon alfa-2a (40KD) and standard
ribavirin in HCV genotype 1 treatment naive patients: efficacy and safety
analysis of the induction phase of the CHARIOT study
First Studies Demonstrating Greater than 60%
Sustained Viral Response Rates with Half the Standard Treatment Duration in
Genotype 1 Chronic Hepatitis C Patients (Vertex press release)
HCV Advocate’s AASLD Conference coverage
Oct-Sep-June 2007
Combination Therapy with HCV Protease Inhibitor
Boceprevir Produces a High Rate of Early Virological Response in Genotype 1
Hepatitis C Patients
-
Some Patients with Genotype 1 Chronic Hepatitis C May
Benefit from Prolonged Treatment with Pegylated Interferon plus Ribavirin
Weight-based Ribavirin Is Superior to the Standard
Fixed Dose in Combination with Pegylated Interferon for Treatment of
Genotype 1 Hepatitis C
-
Pharmasset Initiates Phase 1 Dose-ranging Study of
R7128 plus Pegasys plus Copegus in Genotype 1, Treatment-naive Hepatitis C
Patients
An Association Unique to HCV Genotype 3
Continue reading "HCV Genotype 3 and Fatty Liver"
DDW 2007 Highlights:
Part 2
Pegylated Interferon Alfa-2a Plus Ribavirin for 16 or
24 Weeks in Patients with Genotype 2 or 3 HCV Infection
Epidemiological
Characteristics and Treatment Outcomes in Individuals with Genotype 4 HCV
Infection
72-week Treatment with Pegylated Interferon plus
Ribavirin Can Produce Sustained Virological Response in Some Prior Relapsers
67% Steatosis in HCV/HIV Coinfected: : Liver inflammation, HCV genotype 3,
and BMI are associated with steatosis, a common finding in
HCV-HIV-coinfected patients.
Both Pegasys/Ribavirin and PegIntron/Ribavirin
Combination Regimens Appear Similar in Efficacy and Safety in HCV Genotype 3
Patients
Treatment with Pegasys Plus Ribavirin in Genotype 2/3
Chronic Hepatitis C Patients with Liver Cirrhosis
Asians with Genotype 1 HCV Respond as Well as Whites
to Interferon-based Therapy
Hepatitis C virus genotype distribution in Myanmar:
Predominance of genotype 6 and existence of
new genotype 6 subtype.
Selected Patients with Genotype 1 HCV May Attain SVR
by Extending Treatment Duration to 72 Weeks
Treatment Duration and Response in Patients with
Genotype 2 or 3 HCV Infection
Sustained Response to Anti-Hepatitis C Virus Drugs Results in
Cure in Virtually All Cases: Presented at EASL
May 2007
Treatment
of hepatitis C virus infection.
HCV Genotype and Disease Progression
HCV Genotype Recombination
16-Week Treatment for Genotype 2
April-March 2007
Interim Results Presented at EASL from PROVE 1
Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype
1 Hepatitis C
48 Weeks & High Ribavirin Dose May Improve SVR Rates
for Genotype 2/3, French study by Bernard Willems
Virological response at 4 and 12 weeks predict high
rates of sustained virological response in genotype 1 patients treated with
peginterferon alfa-2a (40KD) plus ribavirin
-
14 Weeks vs 24 Weeks Peg/RBV for Genotypes 2/3
In vitro
Does the Natural History of Hepatitis C Vary According
to HCV Genotype?
Treatment of Chronic Hepatitis C Virus in African Americans With Genotypes 2
and 3 -
Report of Hepatitis C Virus Genotype Recombination
PEGASYS(R) Gets European Approval for a Shorter Treatment Duration for Some
Genotype 1 and 4 Hepatitis C Patients who Show a Rapid Response to Therapy
-
Human Genome Sciences Initiates Phase 3 Clinical Trial of Albuferon(R) With
Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C Genotypes 2
and 3 -
Liver Steatosis in Genotype 4 Patients Is Mainly Due
to Metabolic Factors
February - January 2007
Liver Steatosis in Genotype 4 Patients Is Mainly Due
to Metabolic Factors
African Americans with Genotype 1 Hepatitis C Less
Likely to Have Steatosis
Impact of Ribavirin Dose Reductions in
Hepatitis C Virus Genotype 1 Patients Completing Peginterferon
Alfa-2a/Ribavirin Treatment
2008
2007
2006
2005 Index Genotype Research
2004 Thru 2001 Index of all Genotype Research
